Cyclo Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Form 4: Cyclo Therapeutics Director William Conkling Receives Stock Grant in Lieu of Cash Compensation
Director William Conkling of Cyclo Therapeutics, Inc. received 27,654 shares of common stock as compensation in lieu of cash.
Director Vivien Wong of Cyclo Therapeutics, Inc. received 25,140 shares of common stock as compensation in lieu of cash.
Form 4: Cyclo Therapeutics Director Shawn Cross Reports Acquisition of Shares in Lieu of Cash Compensation
Director Shawn Cross acquired 28,597 shares of Cyclo Therapeutics common stock on February 27, 2025, in lieu of cash compensation.
Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired 33,311 shares of common stock as compensation in lieu of cash.
Director C.E. Rick Strattan acquired 30,169 shares of Cyclo Therapeutics common stock in lieu of cash compensation.
Director Francis Patrick Ostronic acquired 70,329 shares of Cyclo Therapeutics common stock in lieu of cash compensation.
Director Markus Sieger reports acquisition and disposal of Cyclo Therapeutics (CYTH) common stock related to director compensation.
Director William S. Shanahan acquired 25,140 shares of Cyclo Therapeutics common stock in lieu of cash compensation for director services.
Rafael Holdings converted $2.5 million of debt into 3,968,254 shares of Cyclo Therapeutics common stock.
William Conkling, a director at Cyclo Therapeutics, received 16,660 shares of common stock in lieu of cash compensation for the third quarter of 2024.
A Cyclo Therapeutics director, Shawn Cross, received 17,228 shares of common stock in lieu of cash compensation for the third quarter of 2024.
William S. Shanahan, a director at Cyclo Therapeutics, received 15,145 shares of common stock in lieu of cash compensation for the third quarter of 2024.
Director Markus Sieger of Cyclo Therapeutics acquired 35,022 shares of common stock in lieu of cash compensation for the third quarter of 2024.
A Cyclo Therapeutics director, C.E. Rick Strattan, received 63,608 shares of common stock in lieu of cash compensation for the third quarter of 2024.
Cyclo Therapeutics director Randall M. Toig acquired 20,067 shares of common stock in lieu of cash compensation for the third quarter of 2024.
Director Vivien Wong of Cyclo Therapeutics received 15,145 shares of common stock in lieu of cash compensation for the third quarter of 2024.
425: Rafael Holdings to Merge with Cyclo Therapeutics in Deal Focused on Niemann-Pick Disease Treatment
Rafael Holdings and Cyclo Therapeutics have entered into a definitive merger agreement to focus on the development of Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1.
William S. Shanahan, a director at Cyclo Therapeutics, Inc., acquired 7,937 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024.
Director William Conkling of Cyclo Therapeutics, Inc. reports acquisition of shares via stock grant in lieu of cash compensation and subsequent disposal.
Director Vivien Wong acquired 7,937 shares of Cyclo Therapeutics common stock on August 16, 2024, in lieu of cash compensation for the second quarter of 2024.
Director Shawn Cross of Cyclo Therapeutics, Inc. received 9,028 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.
Director Randall M. Toig of Cyclo Therapeutics, Inc. received 10,516 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.
C.E. Rick Strattan, a director of Cyclo Therapeutics, acquired 9,524 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024.
Director Markus Sieger of Cyclo Therapeutics, Inc. received 18,354 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.
Cyclo Therapeutics has entered into a Note Purchase Agreement with Rafael Holdings, issuing a $2 million convertible promissory note to bolster working capital.
Director William S. Shanahan received shares and options from Cyclo Therapeutics as part of the company's compensation policy.
Joshua M. Fine, CFO of Cyclo Therapeutics, Inc., reports the acquisition of stock options.
Jeffrey Tate, COO of Cyclo Therapeutics, acquired stock options on June 3, 2024.
Michael Eric Lisjak, Chief Regulatory Officer of Cyclo Therapeutics, Inc., reports the acquisition of stock options.
Director Markus Sieger received shares and options from Cyclo Therapeutics as part of his compensation, according to a recent SEC filing.